Oct 29, 4:03 PM ET
Gilead Sciences announced its third quarter 2026 financial results, reporting a 13% increase in total product sales to $8.3 billion driven by growth in HIV and oncology products. The company also raised its full-year 2026 base business revenue guidance for the year, bringing total increases to $1.6 billion since the start of the year.
- Total third quarter 2026 product sales increased 13% year-over-year to $8.3 billion.
- GAAP diluted earnings per share was $1.94 for the third quarter of 2026 compared to $2.43 in the prior year period.
- Full-year 2026 product sales guidance was raised to a range of $31.0 billion to $31.3 billion.
- As of September 30, 2026, cash, cash equivalents and marketable debt securities totaled $6.4 billion.
Read the filing on SEC.gov ↗
Aug 4, 4:03 PM ET
Gilead reported second quarter 2026 total revenues of $7.8 billion, up 10% from a year earlier, and raised its full-year 2026 product sales guidance. The company posted a GAAP diluted loss of $(8.45) per share, driven by $11.2 billion of acquired in-process R&D expenses tied to recent acquisitions, and its full-year GAAP loss per share guidance was widened.
- Total revenues rose 10% to $7.8 billion; HIV product sales rose 12% to $5.7 billion.
- GAAP diluted loss per share was $(8.45), compared with diluted earnings of $1.56 a year earlier, mainly due to $(9.08) per share of acquired IPR&D and tax expenses.
- Full-year 2026 GAAP diluted loss per share guidance is $(3.75) to $(3.40), down from the prior $(3.25) to $(2.85); product sales guidance is $30.1 billion to $30.4 billion, up from $30.0 billion to $30.4 billion.
- Cash, cash equivalents and marketable debt securities were $3.2 billion at June 30, 2026, compared with $10.6 billion at December 31, 2025.
Read the filing on SEC.gov ↗
May 20, 4:15 PM ET
Gilead Sciences issued $3.0 billion of senior notes in four tranches, under an underwriting agreement dated May 14, 2026, and a supplemental indenture dated May 20, 2026. The company said it will use the net proceeds for general corporate purposes, which may include acquisitions, investments and other strategic transactions.
- Four series: $500 million 4.250% notes due 2028, $1.0 billion 4.400% notes due 2029, $1.0 billion 4.600% notes due 2031, and $500 million 4.900% notes due 2034
- Notes were sold in a public offering under shelf registration Form S-3 (File No. 333-273745); underwriters include Barclays Capital, BofA Securities and Citigroup Global Markets
- Indenture restricts secured debt, sale and leaseback transactions, and mergers or asset transfers, and requires an offer to repurchase notes upon certain change of control events
Read the filing on SEC.gov ↗
May 7, 4:03 PM ET
Gilead reported first-quarter 2026 total revenue of $7.0 billion, up 4% from a year earlier, and GAAP diluted EPS of $1.61 versus $1.04. The company cut its full-year 2026 GAAP diluted EPS guidance to a loss of $(3.25) to $(2.85) from $6.75 to $7.15, citing anticipated acquired IPR&D charges of $11.5 billion and financing costs tied to the Arcellx, Ouro and Tubulis acquisitions, while raising its product sales guidance.
- Q1 2026 total revenues rose 4% to $7.0 billion; GAAP diluted EPS was $1.61 versus $1.04 and non-GAAP diluted EPS was $2.03 versus $1.81.
- Full-year 2026 GAAP diluted EPS guidance is $(3.25) to $(2.85), down from $6.75 to $7.15; non-GAAP guidance is $(1.05) to $(0.65), down from $8.45 to $8.85.
- Full-year 2026 product sales guidance was raised to $30.0 billion to $30.4 billion from $29.6 billion to $30.0 billion.
- Cash and marketable debt securities fell to $8.6 billion at March 31, 2026, from $10.6 billion at December 31, 2025; the Board declared a $0.82 quarterly dividend payable June 29, 2026.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.